Objective To investigate the value of CT taking WO3-x@BSA nanoparticles as contrast agents.Methods CT values of WO3-x@BSA nanoparticles and the iohexol contrast agents at different concentrations were measured.When the tube voltage was the same,CT values of the tungsten at different concentrations were measured,and the relationship curve of CT values and the concentrations,the tube voltages and CT values were plotted.The animal models were performed to observe CT imaging in vivo and in vitro.WO3-x@BSA nanoparticles were injected through tail vein and intraperitoneally of rats in vivo.In fresh pig liver,WO3-x@BSA nanoparticles were injected by portal vein.Results CT value of the tungsten was higher than the iodine at the same concentration,and the imaging signal of the tungsten was more significant than the iodine.The amount of WO3-x@BSA was less than the iohexol contrast agent reaching to the same CT value.WO3-x@BSA nanoparticles could reach the organs of various tissues in SD rats through different ways and showing the high density sig nal.WO3-x@BSA nanoparticles were also injected into the fresh in-vitro liver of pig,and could diffuse and distribute along with the blood vessels with good CT imaging.Conclusion As a novel CT contrast agent,WO3-x@BSA nanoparticles can be used to get good CT imaging.

Objective:To evaluate the clinical applicability of CT angiography (CTA) for locating the perforator vessels of anterolateral thigh flap(ALTF) and the effects of individualized ALTF designed by CTA for the reconstruction of the soft tissue defects of tongue after the resection of tongue carcinoma.Methods:21 patients with tongue squamous cell carcinoma underwent CTA for locating the perforator vessels of ALTFs and for the design of individualized ALTFs before operation.The patients underwent soft tissue defect reconstruction with individualized ALTFs after tumor removal.Results:All the operations came off as preoperative designed,the intraoperative findings of the blood vessel alignment were consistent with the preoperative CTA results.The size of flaps was 6.0 cm × 5.0 cm-11.0 cm× 8.5 cm.20 ALTFs survived,2 ALTFs appeared vascular crisis,1 remained survival and the other was necrotic after surgical exploration.During 6 ～ 60 momhs of follow-up,the survival condition of flaps and the wound healing condition were both satisfactory.1 patient died because of distant metastasis 18 months after operation.20 patients reminded free of carcinoma and satisfied with the reconstructive effects of chewing,swallowing and linguistic function.Conclusion:CTA can accurately locate perforator vessels for the design of individualized AFLT.AFLT designed by CTA is an ideal choice for the reconstruction of postoperative soft tissue defects after resection tongue carcinoma.

The upper limb dysfunction resulted from stroke has a high incidence and is hard to recover,seriously affecting the daily life and life quality of patients.The nerve tissue damage caused by stroke usually leads to the injuries of movement,sensory,cognitive and etc.The effective rehabilitation therapy can promote the rebuilding of the surviving cranial nerves to enhance the function and ability.As a modem intelligent nerve rehabilitation technology,brain-machine interface (BCI) directly builds the exchange channel between the brain and the surrounding environment.BCI extracts the brain's neural activity information,and transfers into the command to drive external equipment.BCI does not rely on the peripheral nerve system and muscle tissue.BCI technology is well suited for neurological rehabilitation training,because the repeated training associated with external equipments and BCI feedback can induce a normal exercise mode,indirectly induced the generation of normal brain signal,and promote brain remodeling,so that improve the patient's athletic ability and exercise control level.In this paper,the research progress of BCI technology for the rehabilitation of the upper limb motor function after stroke was reviewed,including the application,the efficacy and the existing limitations.

Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; complications ; Spondylitis, Ankylosing ; complications